Early access
Sign in
Taking people in United KingdomNo phase

Manganese heart MRI scans in heart failure with preserved ejection fraction

Uses manganese heart scans to study heart failure and diabetes.

Key facts

Who runs it
University of Leicester
Where
Leicester, United KingdomSee the site
Trial code
Registry title
Manganese-enhanced Magnetic Resonance Imaging (MEMRI) in Heart Failure With Preserved Ejection Fraction
Status
Recruiting
People taking part
60 people, planned
Started
10 Oct 2024
Expected to end
Feb 2036
Type of study
Observational, 3 groups
Treatments tested
  • Minnesota Living with Heart Failure Questionnaire
  • Echocardiogram
  • Six-minute walk test
  • Manganese-enhanced MRI and 31-P magnetic resonance spectroscopy
  • Cardiovascular magnetic resonance scan
  • Blood tests
Record updated
30 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with heart failure with preserved ejection fraction (HFpEF), with or without type 2 diabetes. It also takes up to 20 healthy volunteers for comparison.

Age
18 years or older
Sex
All sexes can join
Disease stage
Heart failure with preserved ejection fraction (LV ejection fraction ≥ 50%), shown by symptoms, signs or a diagnosis, or by a score of ≥5 points on the HFA-PEFF diagnostic algorithm. Not in decompensated heart failure.
Earlier treatment
No investigational drug or device within 30 days before joining.

Main reasons for not taking part

  • Type 1 diabetes
  • Pregnant or breast-feeding, or women who could have a child and have no negative pregnancy test
  • Heart attack in the previous 3 months
  • Baseline eGFR < 30mL/min/1.73m2, or abnormal liver tests or liver disease
  • Any reason you cannot have an MRI, including implanted devices or pacemakers

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Capacity to provide informed consent
  • Symptoms (e.g. breathlessness, orthopnoea, ankle swelling, fatigue), signs (e.g. elevated jugular venous pressure, peripheral oedema, third heart sound) or established diagnosis of HF with LV ejection fraction ≥ 50%, or
  • Meets HFpEF diagnostic criteria in accordance with the HFA-PEFF diagnostic algorithm form the Heart Failure Association of the European Society of Cardiology, in which a score ≥5 points confirms diagnosis of HFpEF

Who cannot take part

  • Receiving an investigational drug or device within 30 days prior to participating in the study
  • Recent myocardial infarction within the previous 3 months
  • Known diagnosis of Type 1 Diabetes
  • Decompensated heart failure or pulmonary oedema
  • Abnormal liver function tests (> 3x upper limit of normal) or history of liver disease
  • Severe native valve disease, restrictive cardiomyopathy, constrictive pericarditis or hypertrophic cardiomyopathy, myocarditis or takotsubo cardiomyopathy
  • History of prolonged corrected QT interval or torsades de pointes
  • Baseline eGFR < 30mL/min/1.73m2
  • Pregnancy or breast-feeding or females of child bearing age without a negative pregnancy test
  • Second- or third-degree atrioventricular block
  • Any contraindications to MRI including implanted devices/pacemakers
  • Known diagnosis of pheochromocytoma

Where in United Kingdom

  • University of LeicesterLeicester, United KingdomContact: Gerry P McCann, MDTaking people

About the trial

What the trial wants to find out

Heart failure with preserved ejection fraction (HFpEF) is a condition in which the heart cannot fill with blood effectively. As a result, people with HFpEF suffer fatigue, breathlessness, and develop swollen limbs. The condition often requires multiple admissions to hospital and is associated with a marked loss of lifespan.

Read full original descriptionShow less

Despite being so common, very little is known about why people develop HFpEF and there are hardly any known treatments. Type 2 diabetes (T2D) is a major risk factor for HFpEF, and people with both HFpEF and diabetes are at a heightened risk of hospitalisation and premature death. It is unclear why the combination of diabetes and HFpEF is particularly harmful. This may be related to the hearts of people with type 2 diabetes being unable to take up the mineral calcium properly, as well as due to their hearts being less energy efficient. Both of these are vital to heart muscle pumping and filling, but until recently it has not been possible to assess these in humans.

New advances in heart MRI scans, with dedicated scanner techniques and dyes (manganese contrast), now allow extremely detailed pictures of heart structure, function, calcium uptake and energy efficiency, all during the same scan. The investigators will enlist 40 volunteers with HFpEF (20 with T2D and 20 without T2D), and up to 20 healthy volunteers, to undergo a heart MRI scan with manganese contrast to assess calcium uptake and energy efficiency. This will allow the comparison of people with HFpEF with and without T2D, to see how their hearts are different to healthy volunteers.

The 3 groups in the trial

  • HFpEF with T2D

    Participants with heart failure with preserved ejection fraction and type 2 diabetes

    Treatment: Minnesota Living with Heart Failure Questionnaire, Echocardiogram, Six-minute walk test, Manganese-enhanced MRI and 31-P magnetic resonance spectroscopy, Cardiovascular magnetic resonance scan, and Blood tests

  • HFpEF without T2D

    Participants with heart failure with preserved ejection fraction but without type 2 diabetes

    Treatment: Minnesota Living with Heart Failure Questionnaire, Echocardiogram, Six-minute walk test, Manganese-enhanced MRI and 31-P magnetic resonance spectroscopy, Cardiovascular magnetic resonance scan, and Blood tests

  • Controls

    Healthy volunteers without heart failure or type 2 diabetes

    Treatment: Minnesota Living with Heart Failure Questionnaire, Echocardiogram, Six-minute walk test, Manganese-enhanced MRI and 31-P magnetic resonance spectroscopy, Cardiovascular magnetic resonance scan, and Blood tests

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Manganese-enhanced Magnetic Resonance Imaging (MEMRI) in Heart Failure With Preserved Ejection Fraction
Plain-language title
Manganese heart MRI scans in heart failure with preserved ejection fractionGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
30 April 2026